Medical Imaging Phantom Market

Executive Summary

Medical Imaging Phantom Market was valued at US $204.21 million in 2021 and is projected to grow at 4.45% CAGR over the forecast period to reach US $265.18 million by 2027. Medical Imaging Phantom Market represented US $17.03 million opportunity over 2019-2021 and estimated to create US $60.97 million opportunity in 2027 over 2021.

Medical Imaging Phantom from Consainsights analyses the Medical Imaging Phantom Market in the Life Sciences industry over the forecast period to 2027.

Medical Imaging Phantom research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Medical Imaging Phantom segmentation includes Product Type, Material, End User and Geography.

Based on the Product Type, the Medical Imaging Phantom analysis covers X Ray Phantoms, Ultrasound Phantoms, MRI Phantoms, Nuclear Imaging Phantoms, Other Product Types.

In Product Type segment, X Ray Phantoms segment has highest cagr growth of 3.95%.

Based on the Material, the Medical Imaging Phantom analysis covers Stimulating Devices, False Organ.

In Material segment, Stimulating Devices segment has highest cagr growth of 3.95%.

Based on the End User, the Medical Imaging Phantom analysis covers Hospitals, Diagnostic Laboratories, Other End Users.

In End User segment, Hospitals segment has highest cagr growth of 3.95%.

Based on the region, the Medical Imaging Phantom analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bartec Technologies Ltd, Biodex Medical System Inc., Carville, Computerized Imaging Reference Systems Inc., Gold Standard Phantoms, Kyoto Kagaku Co. Ltd, Leeds Test Object Ltd, Modus Medical Device Inc., Pure Imaging Phantoms, PTW Freiburg GmbH and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, X Ray Phantoms segment has the highest revenue of US $83.70 million and is expected to grow at CAGR of 3.95% by 2027 X Ray Phantoms segment has highest cagr growth of 3.95%.

X Ray Phantoms

X Ray Phantoms segment was valued at US $76.72 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $108.68 million by 2027. X Ray Phantoms segment represented US $6.98 million opportunity over 2019-2021 and estimated to create US $24.99 million opportunity in 2027 over 2021.

Ultrasound Phantoms

Ultrasound Phantoms segment was valued at US $47.28 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $66.98 million by 2027. Ultrasound Phantoms segment represented US $4.30 million opportunity over 2019-2021 and estimated to create US $15.40 million opportunity in 2027 over 2021.

MRI Phantoms

MRI Phantoms segment was valued at US $30.36 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $43.01 million by 2027. MRI Phantoms segment represented US $2.76 million opportunity over 2019-2021 and estimated to create US $9.89 million opportunity in 2027 over 2021.

Nuclear Imaging Phantoms

Nuclear Imaging Phantoms segment was valued at US $17.33 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $24.55 million by 2027. Nuclear Imaging Phantoms segment represented US $1.58 million opportunity over 2019-2021 and estimated to create US $5.64 million opportunity in 2027 over 2021.

Other Product Types

Other Product Types segment was valued at US $15.50 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $21.95 million by 2027. Other Product Types segment represented US $1.41 million opportunity over 2019-2021 and estimated to create US $5.05 million opportunity in 2027 over 2021.

Material

Introduction

In 2021, Stimulating Devices segment has the highest revenue of US $149.74 million and is expected to grow at CAGR of 3.95% by 2027 Stimulating Devices segment has highest cagr growth of 3.95%.

Stimulating Devices

Stimulating Devices segment was valued at US $137.26 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $194.45 million by 2027. Stimulating Devices segment represented US $12.49 million opportunity over 2019-2021 and estimated to create US $44.71 million opportunity in 2027 over 2021.

False Organ

False Organ segment was valued at US $49.92 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $70.73 million by 2027. False Organ segment represented US $4.54 million opportunity over 2019-2021 and estimated to create US $16.26 million opportunity in 2027 over 2021.

End User

Introduction

In 2021, Hospitals segment has the highest revenue of US $126.26 million and is expected to grow at CAGR of 3.95% by 2027 Hospitals segment has highest cagr growth of 3.95%.

Hospitals

Hospitals segment was valued at US $115.73 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $163.95 million by 2027. Hospitals segment represented US $10.53 million opportunity over 2019-2021 and estimated to create US $37.70 million opportunity in 2027 over 2021.

Diagnostic Laboratories

Diagnostic Laboratories segment was valued at US $57.78 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $81.86 million by 2027. Diagnostic Laboratories segment represented US $5.26 million opportunity over 2019-2021 and estimated to create US $18.82 million opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $13.67 million in 2019 and is projected to grow at 3.95% CAGR over the forecast period to reach US $19.37 million by 2027. Other End Users segment represented US $1.24 million opportunity over 2019-2021 and estimated to create US $4.45 million opportunity in 2027 over 2021.